Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation is about hair loss treatments, specifically discussing GHK-Cu, with some users suggesting Minoxidil as more effective. OP is looking for a GHK-Cu product available in Europe.

The conversation discusses using GHK-Cu copper peptide from Bulk Naturals for hair loss, comparing its price and quality to Peptide Sciences. Concerns about the product's legitimacy are mentioned, but COA documents are available.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Using a face serum with 1% copper peptides (ghk-cu) on the scalp as an adjunct to finasteride and minoxidil for hair growth and scalp health. The user is unable to find a specific hair serum with ghk-cu locally.

The user has been using Minoxidil 1.5 times a day for 4 months, Finasteride 1mg for 3 months, and microneedling once a week. They are unsure about their progress due to colorblindness, but another user noted some improvement.

RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.

A 49-year-old is using finasteride, minoxidil, tretinoin, and ketoconazole shampoo to combat advanced hair loss and hopes for enough regrowth to consider a hair transplant. Progress is slow, but some improvement is noted by others.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

The conversation discusses the steps for microneedling, specifically differentiating between medical needling (0.5-1.5mm) and cosmetic needling (0.3mm). It emphasizes the importance of cleaning and disinfecting before microneedling, regardless of needle length.

The user started using finasteride, minoxidil, and biotin on January 22nd and shared their hair regrowth results. They have a 4C hair type and are taking these treatments daily while exercising twice a week.

The user is trying a new hair loss regimen including Spirolactone, Finasteride, oral Minoxidil, microneedling, and various supplements. They are experiencing increased shedding and seeking advice on microneedling and treatment effectiveness.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

GHK-Cu helped control Seborrheic Dermatitis and reduced scalp irritation, with no immediate change in hair fall or growth. Users reported reduced flakes and healthier skin using GHK-Cu topically.

Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.

A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.

The user has been using topical minoxidil and finasteride for four months, along with microneedling and Nizoral, noticing thicker lashes and eyebrows but not much scalp hair growth. They apply the treatment twice daily with a 5% minoxidil and 0.3% finasteride solution.

A user experienced side effects from finasteride and switched to using GHK-Cu for hairline improvement, noticing some positive changes after three months. They used a 2mg daily dose via subcutaneous injections and reported increased hair density and baby hairs, though results were not dramatic.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.